

Company name: NeuroTrigger Website: www.nt-med.com

CEO name: Nikolai Kunicher.

CATEGORY: Medical Devices

SESSION: Illuminating the Path; Innovations and Challenges in Eye Care

- **Executive Summary**

Millions suffer from impaired blinking due to facial paralysis and neurodegenerative conditions. We developed the first and only FDA-cleared eyelid pacemaker, restoring natural blinking and improving patient quality of life. Our razor-razor blade model ensures a growing revenue stream through disposable components. With a world-class team and scale-up completion nearing, we are set to initiate market penetration, driving innovation and accessibility in the upcoming months.

- **Core Technology**

We developed the only FDA-cleared eyelid pacemaker, a groundbreaking solution that restores natural blinking and significantly improves patient quality of life. Our user-friendly system provides automated eyelid stimulation through three key components:

- A wearable, reusable, and rechargeable stimulator
- Daily disposable electrodes
- A mobile app for customizable control of blink pace and pulse intensity

- **Product Profile/Pipeline**

Our FDA-cleared device is ready for market entry, marking a significant advancement in restoring natural blinking. We are finalizing scaling up production and preparing for a commercial launch in the upcoming months. With a serviceable addressable market of \$4.4B, we are positioned for strong growth. As sales commence this year, we plan to engage strategic partners for potential collaboration and market expansion.

- **Business Strategy**

Our razor-razor blade business model, centered on daily disposable electrodes, ensures a growing revenue stream as the market expands annually. We will first target facial paralysis patients, providing them with an effective blinking solution, before expanding to neurodegenerative conditions, including Parkinson's disease. This strategic approach allows us to maximize market impact while continuously scaling to meet the evolving needs of patients worldwide.

- **What's Next?**

Parallel to our commercial launch, we aim to conduct post-market clinical validation to support reimbursement strategies. As we progress, we are actively seeking strategic

partnerships and are currently engaged in a Series A funding round to accelerate market entry and adoption.